Can we count your visit with Google Analytics? No ads, no profiles. Details
DVA
NYSEAnalystsBuy7+14%Health Care · Health Care Providers & Services
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: duopoly with $FMS in US outpatient dialysis (~70% combined share of ~550k US ESRD patients); aging demographics + rising diabetes/hypertension prevalence drive steady ~1-2% annual treatment growth. Commercial-payor mix arbitrage is the entire economic engine - ~10-12% of treatments produce ~100%+ of segment operating income; Medicare reimbursement (~$280/treatment) is roughly breakeven.
Berkshire owns ~45% of shares outstanding, continues buying back through DVA's tender participation. Integrated Kidney Care (IKC) pivot toward value-based / capitated contracts is the long-duration optionality.
(1) duopoly pricing power + structural patient growth; (2) Berkshire backstop + aggressive buybacks shrinking float ~5-7%/yr; (3) IKC scaling toward profitability could re-rate multiple; (4) GLP-1 long-term tail risk for diabetes/CKD progression appears overstated near-term - pipeline of ESRD patients already locked in for 5-10 yrs; (5) international expansion (LatAm, Europe, Asia) adds non-US growth leg.
(1) GLP-1 adoption ($LLY $NVO) compresses incidence growth on a 5-10yr horizon; (2) commercial-payor erosion risk from MA plan steerage + payor consolidation; (3) ESRD treatment-choice legislation (state-level) periodically threatens commercial subsidy; (4) staffing inflation + nurse shortage pressure clinic-level margins; (5) Medicare Advantage shift dilutes the lucrative employer-commercial mix; (6) AKI / cyberattack operational risk (2024 outage reminder).
It reads our $DVA data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.